A 79-Year-Old Woman With Multiple Myeloma

Video

Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.

Case: A 79-Year-Old Woman with Multiple Myeloma

Initial Presentation

  • A 79-year-old woman presented with intermittent nausea, decreased appetite and tingling and numbness in her feet bilaterally
  • PMH: HTN, medically controlled
  • PE: thin, tired appearing woman, otherwise unremarkable; grade I peripheral neuropathy
  • ECOG PS 0


Clinical Workup

  • Labs: Hb 9.6 g/dL, calcium 10.5 mg/dL, LDH 210 U/L, creatinine 1.1 mg/dL, albumin 3.8 g/dL, beta-2 microglobulin 3.2 mcg/mL, M-protein 2.9 g/dL, serum free kappa light chains 4.4 mg/dL, CLCr 35mL/min
  • Hepatitis B and C negative
  • Skeletal survey and MRI showed a lytic lesion in her spine L3/L4
  • Bone marrow shows 45% clonal plasma cells IgG k
  • FISH: hyperdiploid
  • Diagnosis: R-ISS stage I MM

Treatment

  • Initiated lenalidomide + bortezomib + dexamethasone for 8 cycles + lenalidomide maintenance for 9 months
  • Follow-up at that time revealed disease progression
  • Initiated selinexor + bortezomib + dexamethasone
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma

GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma

April 23rd 2024
Article

At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

The Myeloma Trial Result I Did Not See Coming

The Myeloma Trial Result I Did Not See Coming

April 17th 2024
Article

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Read More

FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

April 12th 2024
Article

The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.

Read More

Targeting Multiple Myeloma With the Latest Therapies

Targeting Multiple Myeloma With the Latest Therapies

April 9th 2024
Article

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Read More

FDA Approves Cilta-Cel for Earlier Lines of R/R Multiple Myeloma

FDA Approves Cilta-Cel for Earlier Lines of R/R Multiple Myeloma

April 6th 2024
Article

The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.

Read More